Sulfonylureas, as a classical hypoglycemic drug, are currently divided into three generations. The first generation of glucose-lowering drugs are basically not used in clinical practice, including toluenesulfonylurea and D860, which are now eliminated due to the relatively large side effects. The second generation of drugs, including glipizide and glipizide, are mainly used to stimulate insulin secretion to achieve the effect of lowering glucose, and are suitable for people whose pancreatic islets are still working normally with more than 30% of islet cells. The third generation of drugs is mainly used clinically is glimepiride, this is currently the strongest among the sulfonylurea drugs to reduce glucose effect and is long-acting, taken once a day, the daily dose is 1-8mg, this is the best clinical effect.